MUNIRA WARD: Open Payments
NPI 1417558990 · RALEIGH, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,397 in 141 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $103 · 2025 $3,397
Food & beverage: $3,397
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $625 |
| Vanda Pharmaceuticals Inc. | 22 | $537 |
| ABBVIE INC. | 19 | $368 |
| Janssen Pharmaceuticals, Inc | 9 | $311 |
| E.R. Squibb & Sons, L.L.C. | 10 | $308 |
| Otsuka America Pharmaceutical, Inc. | 17 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $263 |
| Teva Pharmaceuticals USA, Inc. | 10 | $234 |
| Alkermes, Inc. | 10 | $211 |
| Indivior Inc. | 6 | $141 |
Products named: INGREZZA, VRAYLAR, HETLIOZ, INVEGA SUSTENNA, COBENFY, CAPLYTA, ARISTADA, AUSTEDO XR.
Industry payments across NC — which companies pay providers there.
